Ensign Peak Advisors, Inc Centessa Pharmaceuticals PLC Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 79,000 shares of CNTA stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,000
Previous 79,000
-0.0%
Holding current value
$1.31 Million
Previous $1.26 Million
4.75%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CNTA
# of Institutions
118Shares Held
124MCall Options Held
7KPut Options Held
220K-
Medicxi Ventures Management (Jersey) LTD20MShares$332 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$166 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$161 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$106 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$96.5 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.57B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...